EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population
Xiao-Rong Yang, Si-Min Zhong, Zhen-Yi Jin, Xīn Gào, Ying Wu, Qing Zhou, Yang-Qiu Li, Si-Yang Maggie Liu, Yi-Long Wu · 2024
Read EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population by Xiao-Rong Yang, Si-Min Zhong, Zhen-Yi Jin, Xīn Gào, Ying Wu, Qing Zhou, Yang-Qiu Li, Si-Yang Maggie Liu, Yi-Long Wu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11632427.txt.
Description
Xiao-Rong Yang and co-authors review two rare gene faults in lung cancer among Chinese patients in this 2024 paper. The faults sit in the EGFR and MET genes, which drive many lung cancers. Both have approved targeted drugs in China, yet the local evidence base is thin.
The review found 111 studies covering nearly 160,000 patients. In the largest studies, the EGFR fault appeared in well under three percent of all cases, and the MET fault in under two percent. Treatments for the first fault helped only modestly, and outcome data for the second were sparse. The authors call for larger studies to set the best care for Chinese patients with these faults.
Catalog record
| CREATOR | Xiao-Rong Yang, Si-Min Zhong, Zhen-Yi Jin, Xīn Gào, Ying Wu, Qing Zhou, Yang-Qiu Li, Si-Yang Maggie Liu, Yi-Long Wu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |